Strimvelis

AXP000211.1 · Viral vector gene therapy

Platform
gammaretroviral vector (MoMLV-derived) ex vivo, autologous CD34+ bone marrow cells
Targets
ADA
Originator
San Raffaele Telethon Institute for Gene Therapy
Sponsor
Fondazione Telethon ETS

Names

NameTypeSource
Strimvelispreferred name, brandcurator, curator
GSK2696273codecurator

Virus

Role
Ex vivo gene transfer
Family
Retroviridae
Virus
murine leukemia virus (NCBI Taxonomy 11786)
Strain
MoMLV-derived gamma-retroviral vector (GSK3336223)
Replication
non replicating
Modifications
replication-deficient gamma-retroviral vector based on Moloney murine leukaemia virus carrying the human ADA cDNA
Transgenes
ADA
Route
ex vivo, intravenous
Carrier
autologous CD34+ enriched bone marrow cells
Source
evidence

Approvals

AgencyRegionDateStatusBrandIndicationSource
EMAEU2016-05-26approvedStrimvelisSevere combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) when no suitable HLA-matched related stem cell donor is availablesource

Clinical trials (5)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT04959890Methodology Study of Retroviral Insertion Site Analysis in Strimvelis Gene TherapyUnknown2021-04-232024-03-3115Severe Combined Immunodeficiency Due to ADA Deficiency
NCT03311074Retroviral Insertion Site Methodology StudyWithdrawnPhase 42020-06-252020-07-090Immune System Diseases
NCT03232203Evaluating the Effectiveness of STRIMVELIS Risk Minimization Measures (RMMs)Completed2018-04-122021-06-2516Severe Combined Immunodeficiency Due to ADA Deficiency
NCT03478670Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)Enrolling by invitation2017-05-052045-12-3150Immunologic Deficiency Syndromes
NCT00598481ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCIDCompletedPhase 22002-10-022011-07-1012Immunologic Deficiency Syndromes

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 38355973Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency.Nature medicine2024cited by trial NCT00598481
PMID 30014500Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis.Hepatology (Baltimore, Md.)2018name in title: Strimvelis
PMID 28319446Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice.Human gene therapy. Clinical development2017cited by trial NCT00598481
PMID 27129325Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Blood2016cited by trial NCT00598481
PMID 22184407Alterations in the adenosine metabolism and CD39/CD73 adenosinergic machinery cause loss of Treg cell function and autoimmunity in ADA-deficient SCID.Blood2012cited by trial NCT00598481
PMID 19179314Gene therapy for immunodeficiency due to adenosine deaminase deficiency.The New England journal of medicine2009cited by trial NCT00598481
PMID 19633200ADA-deficient SCID is associated with a specific microenvironment and bone phenotype characterized by RANKL/OPG imbalance and osteoblast insufficiency.Blood2009cited by trial NCT00598481
PMID 19652199Integration of retroviral vectors induces minor changes in the transcriptional activity of T cells from ADA-SCID patients treated with gene therapy.Blood2009cited by trial NCT00598481
PMID 18218852Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients.Blood2008cited by trial NCT00598481

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 42648741Implementation and use of risk minimization control tools in the EU: A multistakeholder survey.British journal of clinical pharmacology2026name in abstract: Strimvelis
PMID 37177842Clinical applications of gene therapy for rare diseases: A review.International journal of experimental pathology2023name in abstract: Strimvelis
PMID 34415514Evaluation of Advanced Therapy Medicinal Products by the National Institute for Health and Care Excellence (NICE): An Updated Review.PharmacoEconomics - open2022name in abstract: Strimvelis
PMID 35368231Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options.Applied health economics and health policy2022name in abstract: Strimvelis
PMID 32154598A systematic review of economic evaluations of advanced therapy medicinal products.British journal of clinical pharmacology2021name in abstract: Strimvelis
PMID 33309881Current Clinical Applications of In Vivo Gene Therapy with AAVs.Molecular therapy : the journal of the American Society of Gene Therapy2021name in abstract: Strimvelis
PMID 34790341An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models.Journal of market access & health policy2021name in abstract: Strimvelis
PMID 30334168Strimvelis® for Treating Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Evaluation.PharmacoEconomics - open2019name in title: Strimvelis
PMID 31662152Transplantation of gene-modified haematopoietic stem cells: Application and clinical considerations.South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde2019name in abstract: Strimvelis
PMID 29159201Interactions between Retroviruses and the Host Cell Genome.Molecular therapy. Methods & clinical development2018name in abstract: Strimvelis
PMID 29491255A Novel Approach to the Treatment of Plasma Protein Deficiency: Ex Vivo-Manipulated Adipocytes for Sustained Secretion of Therapeutic Proteins.Chemical & pharmaceutical bulletin2018name in abstract: Strimvelis
PMID 29625577Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID.Orphanet journal of rare diseases2018name in title: Strimvelis
PMID 31282760The rapidly evolving state of gene therapy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology2018name in abstract: Strimvelis
PMID 27548881The potential of toxin-based drug delivery systems for enhanced nucleic acid therapeutic delivery.Expert opinion on drug delivery2017name in abstract: Strimvelis
PMID 27762892Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View.Tissue engineering. Part B, Reviews2017name in abstract: Strimvelis
PMID 28148554Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis.EMBO molecular medicine2017name in title: Strimvelis
PMID 28396566Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products.EMBO molecular medicine2017name in abstract: Strimvelis
PMID 28560211Advanced Therapy Medicinal Products for Rare Diseases: State of Play of Incentives Supporting Development in Europe.Frontiers in medicine2017name in abstract: Strimvelis
PMID 28847159Twenty-Five Years of Gene Therapy for ADA-SCID: From Bubble Babies to an Approved Drug.Human gene therapy2017name in abstract: Strimvelis
PMID 27267267Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID.Human gene therapy. Clinical development2016name in title: Strimvelis
PMID 27410196Gene therapy for severe combined immune deficiency poised for European approval: If green-lighted, Strimvelis would provide additional treatment option for second most common form of disease.American journal of medical genetics. Part A2016name in title: Strimvelis
PMID 27419862Gene Therapy for "Bubble Boy" Disease.Cell2016name in abstract: Strimvelis
PMID 27763769Standing on the Shoulders of Stem Cell Gene Therapists: History, Hyperbole, and Hope for the Future.Human gene therapy. Clinical development2016name in abstract: Strimvelis

Notes

Autologous CD34+ bone-marrow cells transduced ex vivo with a replication-deficient MoMLV-derived gamma-retroviral vector (GSK3336223) carrying the human ADA cDNA; single intravenous infusion. EU marketing authorisation 2016-05-26, originally GSK, transferred to Orchard Therapeutics and then to Fondazione Telethon; still authorised. Development code GSK2696273.

How to cite

Strimvelis (AXP000211.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000211.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.